Recessive Dystrophic Epidermolysis Bullosa Clinical Trial
Official title:
A Prospective, Observational, Long-Term Follow-Up (LTFU) Study to Evaluate the Long-Term Safety of the Krystal Biotech, Inc. Gene Therapy Backbone Products Using HSV-1 Backbone
The main objective of this prospective, observational, long-term follow-up (LTFU) study is to evaluate the long-term safety profile of the gene therapy products evaluated by Krystal Biotech, Inc. which have a shared backbone of HSV-1, in participants who received at least one dose of investigational product (IP).
Due to the guidelines for gene therapy for vectors which may undergo latency/ reactivation, Krystal Biotech, Inc. has established a Long-Term Follow-up Protocol which will identify and mitigate the long-term risks to the participants receiving their gene therapy products and capture delayed adverse events in participants, annually, for 5-years following the last study visit. Additionally, it will allow the Sponsor to further understand the persistence of the gene therapy products used in their parent treatment protocols. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02493816 -
Safety Study of Gene-modified Autologous Fibroblasts in Recessive Dystrophic Epidermolysis Bullosa
|
Phase 1 | |
| Completed |
NCT04599881 -
A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa
|
Phase 2 | |
| Completed |
NCT04520022 -
Safety and Effectiveness Study of Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients With RDEB
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03632265 -
Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
|
Phase 3 | |
| Recruiting |
NCT05944250 -
A Pilot Study to Evaluate a Temporary Skin Substitute (Spincare® Matrix) for Wound Healing in RDEB Patients
|
N/A | |
| Completed |
NCT04917874 -
A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa
|
Phase 3 | |
| Not yet recruiting |
NCT04285294 -
Molecular Signatures of Cutaneous Squamous Cell Carcinoma During Recessive Dystrophic Epidermolysis Bullosa
|
||
| Active, not recruiting |
NCT04213261 -
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa
|
Phase 3 | |
| Active, not recruiting |
NCT02323789 -
Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01874769 -
Study of Immune Tolerance and Capacity for Wound Healing of Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
|
N/A | |
| Recruiting |
NCT03392909 -
Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
|
Phase 1/Phase 2 | |
| Completed |
NCT03752905 -
A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
|
Phase 1/Phase 2 | |
| Terminated |
NCT02984085 -
Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With RDEB.
|
Phase 1/Phase 2 | |
| Completed |
NCT04227106 -
Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
|
Phase 3 | |
| Completed |
NCT02698735 -
Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT03012191 -
Gentamicin for RDEB
|
Phase 1/Phase 2 | |
| Completed |
NCT03529877 -
Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa
|
Phase 1/Phase 2 | |
| Completed |
NCT05143190 -
Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)
|
Phase 2 | |
| Recruiting |
NCT04177498 -
Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC
|
Early Phase 1 | |
| Completed |
NCT04491604 -
Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB
|
Phase 3 |